. 2016 Oct;5(5):511–516. doi: 10.21037/tlcr.2016.10.14

Table 1. Survival data according to KRAS status in blood.

Author, year	Study population (n)	NSCLC Stage	Therapeutic regimen	Specimen type	PFS (months)	P value (PFS)	OS (months)	P value (OS)
Camps C. et al., (30) 2005	67	IIIB or IV	Chemotherapy	Serum	KRAS +: 7.3	0.2300	KRAS +: 11.4	0.2800
Camps C. et al., (30) 2005	67	IIIB or IV	Chemotherapy	Serum	WT: 5.5	0.2300	WT: 12.5	0.2800
Gautschi O. et al., (31) 2007	175	I, II, III (A/B) or IV	Surgery + chemotherapy	Plasma	–	–	Worse OS of patients with mutant plasma KRAS	0.0370
Wang S. et al., (32) 2010	120	IIIB or IV	EGFR-TKI	Plasma	KRAS+: 2.5	<0.0010	KRAS +: 16.9	0.8270
Wang S. et al., (32) 2010	120	IIIB or IV	EGFR-TKI	Plasma	WT: 8.8	<0.0010	WT: 20.3	0.8270
Nygaard AD. et al., (33) 2013	246	III or IV	Chemotherapy	Plasma	KRAS +: 3.0	0.0043	KRAS +: 4.8	0.0002
Nygaard AD. et al., (33) 2013	246	III or IV	Chemotherapy	Plasma	WT: 5.6	0.0043	WT: 9.5	0.0002
Kim ST. et al., (34) 2013	57	IIIB and IV	EGFR-TKI	Serum	–	–	KRAS +: 3.9	0.4520
Kim ST. et al., (34) 2013	57	IIIB and IV	EGFR-TKI	Serum	–	–	WT: 10.4	0.4520
Nygaard AD. et al., (35) 2014	69	III or IV	Chemotherapy	Plasma	KRAS +: 2.1	0.0100	KRAS +: 3.6	0.0300
Nygaard AD. et al., (35) 2014	69	III or IV	Chemotherapy	Plasma	WT: 5.5	0.0100	WT: 8.4	0.0300
Ai B. et al.,(16) 2016	meta-analysis (30,31,33,35)	III or IV	Chemotherapy	cfDNA	No significant differences	0.4500	No significant differences	0.8900

NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival; EGFR, epidermal growth factor receptor; cfDNA, circulating free DNA.